In addition to tumor PD-L1 expression, tumor mutational burden, tumor lymphocyte infiltrate, peripheral blood biomarkers, and the gut microbiota are emerging biomarkers for checkpoint inhibitor-based immunotherapy14–18. This evidence concerns the gene CD274 and neoplasm.